Drug Trial Radar · NCT06825858
A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
9
Planned (sponsor's estimate)
Start
Apr 7, 2025
Primary completion
Jan 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Chengdu Origen Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
VAN-2401 is Phase I clinical trial to assess the safety and tolerability of KH658 in subjects with neovascular AMD. KH658 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral vector. The standard of care for patients with neovascular AMD are anti-VEGF treaments, which have demonstrated improvement in vision and reduction in fluid. A one time placement of a product which inhibits VEGF has the potential to reduce the patient burden of regular ocular injections.
Conditions
- Age-Related Macular Degeneration
Interventions
KH658Drug
KH658: AAV vector containing a coding sequence for an anti-VEGF protein
Primary outcomes
What the sponsor says the trial is designed to measure.
- SafetyTime frame: 52 Weeks
- SafetyTime frame: 52 Weeks
- SafetyTime frame: 24Weeks
- Rescue InjectionsTime frame: 24Weeks
- Rescue InjectionsTime frame: 52Weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Kanghong Investigative Site
Phoenix, Arizona
Kanghong Investigative Site
Lemont, Illinois
Kanghong Investigative Site
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.